Project Grant R44CA291331
Award Date
9/9/24
Completion Date
8/31/26
Dollars Obligated
$1.4M
Federal Agency
National Cancer Institute
Awardee
Avantgen Inc. (WLNHKNPNT2M7)
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This Project Grant award, valued at $678,101, was provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) to The Regents of the University of California, San Francisco (UCSF). The funding supports a 5-year research project to develop a novel radioimmunotherapy targeting the active conformation of integrin beta-2 as a potential best-in-class treatment for acute myeloid leukemia (AML). The key objectives are to: 1) evaluate the preclinical efficacy...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,000 to Kure Ai Inc. to develop a novel CAR-T cell therapy product targeting the MR1 antigen expressed on the surface of various tumor cells, including acute myeloid leukemia (AML) and glioblastoma. The key objectives are to: 1) assess MR1 expression in primary patient AML and glioblastoma samples, 2) perform mouse efficacy studies using AML and glioblastoma models, and 3)...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $768,437.00 to the Sanford Burnham Prebys Medical Discovery Institute (SBP) to conduct research aimed at identifying chemical compounds that inhibit the chromatin reader SGF29, which has been identified as a regulator of oncogene transcription in acute myeloid leukemia (AML). The goal of the project is to implement high-throughput screening assays developed by SBP to discover...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) to the Foundation For Applied Molecular Evolution, Inc. provides $215,564 to develop new molecular reagents called "AegisBody" and "AegisCleavers" for cancer research. These novel reagents can bind to and covalently cleave target proteins, like the cancer-relevant PD-L1 protein, unlike traditional antibodies. The goal is to create these more stable and cost-effective...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $542,663 to The University of Texas M.D. Anderson Cancer Center to conduct preclinical research on novel therapies for acute myeloid leukemia (AML). The research aims to evaluate the efficacy of BRG1/BRM antagonists, such as the inhibitor FHD-286 and the degrader AU15330, in overcoming resistance to menin inhibitors in AML with MLL rearrangement or mutant NPM1. The studies...
This Project Grant award from the National Cancer Institute (NCI), under the Federal Grant Program 93.395 Cancer Treatment Research (CFDA 93.395), is funding the development of novel chimeric antigen receptor (CAR) T-cell therapies targeting the U5 small nuclear ribonucleoprotein (U5 snRNP) complex for the treatment of acute myeloid leukemia (AML). The $402,600 award, granted on Apr 3, 2025, supports research by the Sloan-Kettering Institute for Cancer Research to: (1) test the efficacy and...
This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Biology Research program (CFDA 93.396), is providing $344,111 to Loyola University of Chicago to conduct research on targeting panoptotic pathways for the treatment of myelodysplastic syndromes (MDS). The primary objectives are to investigate whether inhibition of RIPK1 and TBK1 can prevent MDS and eliminate mutant hematopoietic stem/progenitor cells, thereby restoring blood cell counts and preventing...
The National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), has awarded a $683,472 Project Grant to the University of Cincinnati to advance pharmacodynamically directed targeted therapy for acute myeloid leukemia (AML). The 5-year project aims to transition the DHODH inhibitor HOSU-53 into clinical trials, starting with a Phase 1 trial in 2025 to evaluate the compound's pharmacokinetics, pharmacodynamics, and ability to eliminate specific AML cell clones....
The National Cancer Institute (NCI) awarded a $1,427,270 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Syntrix Biosystems Inc. in Federal Way, WA. The grant, awarded on September 16, 2024, will fund a dose expansion study of the investigational drug SX-682, both alone and in combination with the hypomethylating agent decitabine, in patients with myelodysplastic syndromes (MDS). MDS is a pre-leukemic condition that often progresses to acute myeloid leukemia (AML), and...
This $194,688 Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) supports research by Indiana University Indianapolis to investigate the role of the GATA2 gene in acute myeloid leukemia (AML) and the MonoMAC syndrome. The key objectives are to: 1) Define the genes regulated by the normal GATA2 protein and how their expression is altered by AML- and MonoMAC-associated GATA2 mutations, using a novel mouse model and overexpression studies in...